Company profile: DrugDev
1.1 - Company Overview
Company description
- Provider of cloud-based, technology-driven solutions for clinical trial operations, connecting investigators, sites, sponsors, and CROs. Offerings include DrugDev Spark; Master Data Management using the DrugDev Golden Number; a Clinical Trial Investigator Database; IQVIA Protocol Design; IQVIA StudyOptimizer; and IQVIA GrantPlan for grants budgeting and e-negotiation.
Products and services
- DrugDev Spark: A cloud-based, unified clinical operations suite that integrates diverse tools and services to streamline clinical trial processes from planning through closeout
- Clinical Trial Investigator Database: A global-scale network that connects investigators and sites with sponsors and CROs, enabling profile creation and access to clinical trial opportunities
- Master Data Management: An enterprise-grade system that uses the DrugDev Golden Number to master disparate data sources, creating a single source of truth for global sites and investigators
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DrugDev
Chemical Computing Group
HQ: Canada
Website
- Description: Provider of research software for computational chemistry, including Molecular Operating Environment (MOE) for molecular modeling and simulations across small molecules, peptides, and biologics; MOEsaic for real-time docking visualization, SAR analysis, and property modeling; PSILO, a protein structure database integrating public, private, and AlphaFold data with cryo-EM support and deposit validation; and a Discovery Platform for chemists, biologists, and crystallographers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chemical Computing Group company profile →
NiKang Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule oncology therapeutics, developing NKT2152, a HIF2α inhibitor in Phase 1/2 for clear cell renal cell carcinoma and other solid tumors; NKT3447, a reversible ATP-competitive CDK2 inhibitor in Phase 1 for solid tumors; KRAS G12D mutation inhibitors; and a SHP2 inhibitor being clinically evaluated by Erasca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NiKang Therapeutics company profile →
123Compliance
HQ: United States
Website
- Description: Provider of compliance-focused solutions for the life science industry, with more than 20 years of experience. As a Salesforce partner, has built and implemented global complaint handling, quality management, regulatory reporting, and document management systems for small and large pharmaceutical and medical device companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 123Compliance company profile →
H1
HQ: United States
Website
- Description: Provider of a health data platform supporting end-to-end therapeutic development for medical companies and healthcare systems. Offerings include Trial Landscape for principal investigator pools, site performance and patient diversity insights; GenosAI for querying trial data; HCP Universe to discover and engage HCPs; Precise doctor directory data; and H1 Connect for global humanitarian missions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full H1 company profile →
IPM.ai
HQ: United States
Website
- Description: Provider of HIPAA-certified machine learning infrastructure for biopharma, delivering AI-powered patient finding, insights-as-a-service, and a system of insight using real-world data to optimize drug development and commercialization. Services include clinical study recruitment, market assessment, and patient journey mapping for specialty and rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IPM.ai company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DrugDev
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DrugDev
2.2 - Growth funds investing in similar companies to DrugDev
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DrugDev
4.2 - Public trading comparable groups for DrugDev
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →